Skip to main content

Panitumumab (Vectibix)

Panitumumab is a for the treatment of metastatic colorectal cancer.

It is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR) and is an antineoplastic agent.

It is administered through intravenous infusion every 2 weeks.

In 2016, it sold €100 million in Europe.

It has an immunogenicity rate of 2%.

Labs that test for drug level:

University of Tours